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1 |  INTRODUCTION
Thyroid gland dysfunction carries a detrimental effect on 
endometrium, ovulatory function, and fertility (from implan-
tation to delivery).1 The incidence of miscarriage, mainly oc-
curs in the first trimester, was found to be higher (6%-15%) 
in patients with hypothyroidism compared to normal pop-
ulation (2.2%) with a higher risk of miscarriage as a result 
of the increase in maternal TSH concentrations. Apart from 
thyroid function, TPOAb were found to be associated with an 
increased miscarriage rate up to 43.9%.2
Many mechanisms have been studied to explain the cause 
of infertility and subfertility in hypothyroid patients includ-
ing associated hyperprolactinemia, gonadotropins ovarian 
axis effects,3 direct ovulatory dysfunction,4 and endometrial 
dysfunction (endometrium-blastocyst interaction).5
However, the underlying pathological mechanisms remain 
unclear. Hypotheses suggest that autoimmune thyroiditis 
may be a part of an immune-mediated disorder or an autoim-
mune polyglandular syndrome, which includes autoimmune 
vasculitis of the placental microvasculature.6 In addition, 
antithyroid antibodies can directly cause hypothyroidism in 
newborns via crossing the placental barrier.7
Recent guidelines recommend that thyroid status and 
TPOAb level to be taken into consideration separately re-
garding levothyroxine (LT4) treatment in infertile women 
especially those who are undergoing assisted reproductive 
techniques (ART).8 However, a considerable number of 
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Methylene tetrahydrofolate reductase (MTHFR) gene mutations could be the cause 
of infertility in hypothyroid patients. Hence, it is worthy to screen for MTHFR gene 
mutations in infertile hypothyroid females and their partners if infertility persists 
after optimizing thyroid function.
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studies which showed that appropriate LT4 treatment (tar-
geting TSH level <2.5  mIU/L) has not been proven to be 
effective in management of infertility in many hypothyroid 
patients.9,10
This study reports two cases of hypothyroidism with a long 
history of infertility in both primary (first case) and second-
ary due to repeated pregnancy loss (second case) who were 
suffering from infertility after optimization of the euthyroid 
state (TSH below 2.5 mIU/ml). After methylene tetrahydro-
folate reductase (MTHFR) gene mutation was detected, the 
patients were able to conceive till full-term when 5-methyl 
tetrahydrofolate (5-MTHF) was supplemented.
2 |  CASE PRESENTATION
2.1 | Case one
A 26-year woman was referred from the gynecology clinic to 
our endocrinology clinic. Her main complaint was inability 
to conceive for 1.5 years. She had no relevant medical his-
tory. She had regular menses. Regarding her family history, 
her father was on treatment for hyperthyroidism.
On examination, her body mass index (BMI): 24.3 kg/m2, 
and blood pressure (BP): 90/60 mm Hg. Her thyroid gland 
was not palpable.
Laboratory investigations showed: TSH  =  5.66  mIU/
mL (0.39-4.16  mIU/L), FT4  =  1  ng/dL (0.8-2  ng/dL), 
FT3 = 2.4 pg/mL (1.4-4.2 pg/mL), and TPOAb > 600  IU/
mL (0-40 IU/mL). Ultrasound neck revealed normal thyroid 
gland volume with heterogeneous hypoechoic pattern.
Based on the aforementioned results, the patient was di-
agnosed with Hashimoto's thyroiditis with subclinical hypo-
thyroidism. The patient was maintained on LT4 (75 mcg/d). 
After 3 months, her test results showed: TSH = 1.32 μIU/mL 
(adjusted according to ATA guidelines to be <2.5 mIU/L), 
FT4 = 1.29 ng/dL, FT3 = 2.7 pg/mL.
The patient became pregnant after three failed trials of in-
duction of ovulation using clomiphene citrate despite a good 
ovarian response. During pregnancy, 5 mg/d folic acid and 
LT4 100 mcg/d were prescribed. However, she had a miscar-
riage at 15th week of gestation.
Infertility workup showed that her partner had normal 
sperm parameters according to WHO criteria, hysterosalp-
ingography and transvaginal ultrasonography revealed no 
abnormalities.
Hormonal profile showed: FSH  =  5.8  mIU/mL (nor-
mal; 3.5-12.5  mIU/mL), LH  =  6.6  mIU/mL (normal; 2.6-
12.6 mIU/mL), PRL = 8 ng/mL (normal; 2-18 ng/mL), and 
AMH = 4 ng/mL (good fertility; 1.68-4.4 ng/mL) which were 
optimal for fertility. Immune markers including antinuclear 
antibody (ANA), antidouble stranded DNA antibody (an-
ti-dsDNA), lupus anticoagulant (LA), and anticardiolipin 
antibody were all negative. In addition, antithrombin III, pro-
tein C, and protein S were negative.
After 6 months of follow-up, keeping TSH below 2.5 μIU/
mL (optimal for pregnancy), she got pregnant again. Low-
dose aspirin, enoxaparin, LT4, and folic acid 5  mg were 
prescribed. Miscarriage occurred at 14th week of gestation, 
despite the last TSH was 0.7  μIU/mL, FT4  =  0.5  ng/dL, 
FT3 = 2.8 pg/mL, and TPOAb = 297 IU/mL.
After 9 months of follow-up, keeping TSH below 2.5 μIU/
mL, TPOAb progressively increased to its previous level 
(>600  IU/mL). Infertility workup revealed that the patient 
was heterozygous for C677T in methylene tetrahydrofolate 
reductase (MTHFR) gene with a normal serum homocyste-
ine (9.8  μmoles/L) level. Consequently, a supplement con-
taining 5-methyl tetrahydrofolate (5-MTHF) 800  µG daily, 
which supported the one-carbon cycle (Zn, B3, B6, B12) 
with cobalamin, low-dose aspirin and LT4 100 mcg/d were 
prescribed.
Two months later, she got pregnant. During the preg-
nancy, she was maintained on low-dose aspirin and LT4 and 
5-MTHF with cobalamin. She gave birth to a healthy female 
baby. Thereafter, TSH = 1.23 μIU/mL, FT4 = 1.15 ng/dL, 
FT3 = 2.53 pg/mL, and TPOAb = 482 IU/mL at 6 months 
after delivery. At 24 months after delivery, TPOAb titer de-
clined further.
2.2 | Case two
A 24-year old woman, who had a six-year-old child, was 
complaining of failure to conceive for 2 years. She was di-
agnosed with hypothyroid due to Hashimoto's thyroiditis 
3 years ago. Induction of ovulation using clomiphene citrate 
failed five times, despite good ovarian response. Her medical 
history only included chronic allergic rhinitis. She was main-
tained on LT4 100 μg. She had been suffering from menor-
rhagia for 6 years. Her family history was irrelevant.
On examination, her BMI: 32.3  kg/m2 and BP: 
90/60  mm  Hg. Her thyroid gland was not palpable. 
TSH  =  3.6  μIU/mL, FT4  =  1.1  ng/dL, FT3  =  2.7  pg/mL, 
and TPOAb = 1950 IU/mL. Ultrasound neck revealed normal 
thyroid gland volume with heterogeneous hypoechoic pattern. 
Upon that she was diagnosed as Hashimoto`s thyroiditis.
LT4 was titrated till reaching a dose of 125  mcg/d. 
After 3 months, TSH = 0.92 μIU/mL, FT4 = 1.69 ng/dL, 
and FT3 = 2.7 pg/mL. In spite of maintaining a TSH level 
below 2.5, the patient still did not conceive. Infertility 
workup for the patient and her husband showed that CASA 
analysis was normal according to WHO parameters, hys-
terosalpingography and transvaginal ultrasonography re-
vealed no abnormalities. Hormonal profile revealed that 
FSH = 4.9 mIU/mL, LH = 4.6 mIU/mL, PRL = 10.3 ng/
mL, and AMH  =  3.7  ng/mL which were optimal for 
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fertility. ANA, anti-dsDNA, LA, antithrombin III, protein 
C, and protein S were all negative.
The couple had experienced two failed invitro fertilization 
(IVF) cycles, with nine metaphase II oocytes injected, six oo-
cytes fertilized, and a total of two embryos transferred. During 
all of the IVF attempts, she was prescribed DHEA 25 mg three 
times a day and a high (5 mg/d) dose of folic acid.
Interestingly, the patient was homozygous for MTHFR 
A1298C and her husband was heterozygous for MTHFR 
C677T mutation. A supplement containing 5-MTHF (Zn, 
B3, B6, B12), low-dose aspirin, and LT4 100 mcg were pre-
scribed. MTHF was prescribed for the husband as well.
She got pregnant after 2 months of keeping TSH below 
2.5  μIU/mL and TPOAb level decreased to 357  IU/mL. 
During pregnancy, she was maintained on low-dose aspirin, 
LT4 150 mcg, enoxaparin 40 mg, and MTHF 500 mg with 
cobalamin 1000 mg.
Unfortunately, the patient stopped the treatment on her own 
after 12 weeks, after which she delivered a baby with multiple 
congenital anomalies who eventually died 3 weeks later.
Six months later, the patient sought medical advice again 
at our clinic and after explaining the importance of her com-
pliance on MTHF plus LT4, enoxaparin 40 mg, and aspirin, 
she got pregnant after 4 months.
During her pregnancy, she was maintained on the same 
previous medications with the same doses. At the 13th week 
of gestation, enoxaparin dose was raised to 60 mg due to poor 
placental perfusion indicated by high resistance index (RI) of 
retro chorionic blood flow (0.33). Eventually, she gave birth 
to a healthy female baby.
3 |  DISCUSSION
3.1 | MTHFR mutation and female 
infertility
For decades, folate is known to be essential for reproduc-
tive health. Not only due to its importance in oogenesis and 
spermatogenesis but also in prevention of perinatal compli-
cations, mainly neural tube defects.11 MTHFR is a crucial 
enzyme involved in the folate cycle and one-carbon cycle. 
It catalyzes the irreversible conversion of 5, 10 MTHF to 
5-MTHF, which serves as a methyl donor in the remethyla-
tion of homocysteine to methionine. The methylation pro-
cess aids in processing amino acids for neurotransmitters, 
detoxification of compounds like homocysteine (Hcy), an-
tioxidation (by glutathione/ hypotaurine) and DNA repair 
(Figure 1).
A missense mutation in exon 4 of the MTHFR gene, a cyto-
sine-to-thymine substitution at position 677 (C677T) that con-
verts an alanine codon to a valine codon, causes thermolability of 
MTHFR.12 A polymorphism in exon 7 of MTHFR results from 
an adenine-to-cytosine substitution at position 1298 (A1298C).13
F I G U R E  1  Schematic figure showing the process by which folate/folic acid is used for methylation & antioxidation. MTHFR, 
methylenetetrahydrofolate reductase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate
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MTHFR polymorphisms were observed. African 
Americans appear to be protected from MTHFR de-
ficiency. Hispanics and Caucasians may be at elevated 
risk due to increased frequencies of C677T and A1298C, 
respectively.14 Based on a global reference for human 
genetic variation, approximately 25% of the global pop-
ulation are carriers of MTHFR C677T, Hispanics being 
the population with the highest frequency (47%), fol-
lowed by Europeans (36%), East Asians (30%), South 
Asians (12%), and Africans (9%). Approximately 13.5% 
of Europeans are homozygous for the variant allele. Also, 
MTHFR A1298C is present in about 25% of the global 
population and occurs with higher frequency in South 
East Asians (42%) and Europeans (31%), followed by 
Hispanics and Africans is 15%. Approximately 11% of 
Europeans are homozygous for the 1298A  >  C variant 
allele.15
MTHFR mutations, especially for C677T and A1298C, 
decrease the enzyme capacity to form 5 MTHF to 70% 
and 40%, respectively.16,17 Moreover, these mutations are 
associated with recurrent miscarriages, which occurs par-
ticularly with large doses of folic acid (4-5  mg/d).18 The 
mechanism of MTHFR-related poor pregnancy outcomes 
may related to hyperhomocysteinemia, premature ovarian 
failure,19 thrombophilia,20 trophoblastic affection,21 preim-
plantation chromosomal anomalies,22 and male spermato-
genesis affection.23
3.2 | MTHFR gene mutation in hypothyroid 
pregnant female: relation to folic acid
Pregnancy is known to be a state of low folic acid level. 
As during pregnancy, folate is required for rapid cell pro-
liferation and tissue growth of the uterus and placenta, fetal 
growth, and expansion of the maternal blood volume.24
Moreover, hypothyroidism has always been associated 
with low folic acid level and a state of hyperhomocyste-
inemea (more than 100%).25 Experimental studies showed 
that MTHFR activity was low in hypothyroidism and high in 
hyperthyroidism.26
In addition to fortifying food with folate, the US Preventive 
Services Task Force recommends that all women be prescribed 
multivitamins containing folic acid at least 1  month prior to 
conception to prevent neural tube defects,27 and increase a 
woman's chances of becoming pregnant.28 To our knowledge, 
there are no guidelines regarding folic acid supplementation 
during the perinatal period in patients with thyroid dysfunction.
Nevertheless, the relationship between the MTHFR mu-
tation and infertility is controversial whether in natural preg-
nancy or ART.29 Even though, it has not been recommended 
to screen for MTHFR gene mutations for outcome of preg-
nancy in ART.30
Based on our cases, it is suggested that the combined in-
teraction of hypothyroidism, pregnancy, and MTHFR muta-
tions may have a synergistic effect on folic acid metabolism 
which will eventually affect pregnancy outcomes and fertility 
in both, male and females.
Finally, the average direct costs of both patients for de-
laying diagnosis of MTHFR gene mutation including of doc-
tor visits, cost of medications, cost of failed ICSI procedure, 
hospital admissions, and cost of laboratory tests without in-
clusion of psychological burden are 90 000 LE. On contrary, 
cost of MTHFR test and treatment for a year is 2100 LE. So, 
it is cost-effective to screen infertile hypothyroid patients for 
MTHFR gene mutations.
4 |  CONCLUSION
To our knowledge, this is the first time alarm directed to 
MTHFR mutations as a suggested cause of infertility and 
miscarriage in hypothyroid patients and their partners. This 
neglected cause could be treated with MTHF supplementa-
tion for MTHFR carriers couples.
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